Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

s of $3.2 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements regarding the potential for commercializing tolevamer in the future, when data from this Phase 3 study of tolevamer will be presented and when the results of the second Phase 3 study of tolevamer will be available. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the actual safety and efficacy of tolevamer; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of tolevamer for CDAD and the timing of such discussions; additional analysis of the data from the first Phase 3 study; the results of the second Phase 3 study and whether such results are consistent with this data; the timing of the second Phase 3 study; and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the qu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:5/20/2008)...ice leads to 100% patient response ... /- BARRX Medical, Inc., a global,tec...day announced the,publication of two related Europ...r early esophageal cancer and pre-cancerous dyspla...n therapy with the HALO ablation,system. Barrett,s...
(Date:5/20/2008)...l/ -- Delcath Systems, Inc.,(Nasdaq: DCTH ) annou...tive,Officer, provided an update on enrollment num...rial today at a gathering of financial and healthc...w 5th Annual Global,Healthcare Conference., Mr. T... for the Phase,III clinical trial of the Company,s...
(Date:5/19/2008)... MORE SCIENCE SUPPORTING THE, THEORY THAT VACCINE...ewswire-USNewswire/ -- A primate model for autism,...s unveiled at the,International Meeting For Autism...scores the critical need for studies into vaccine ...n of autistic children. The National,Autism Associ...
(Date:5/19/2008)...ss Shionogi Phase 3 results on .../- InterMune, Inc.,(Nasdaq:...development of,pirfenidone for the treatment of id...st Track" designation from the U.S. Food and Drug,...that the FDA reserves for,a drug intended to treat...
Breaking Medicine Technology:Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 2Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination 3Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited 2Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited 3UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism 2InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA 2InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA 3Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 1Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 2Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 3Global Health and Business Leaders Announce 36 Month Effort to Expand Malaria Control in Africa 3B 3 5 Million Lives Could be Saved in Five Years Stu 10123 4Metabolic syndrome affects nearly 1 in 10 US teens 10120 1Metabolic syndrome affects nearly 1 in 10 US teens 10120 2Metabolic syndrome affects nearly 1 in 10 US teens 10120 3NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 10117 1NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 10117 2NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 10117 3Bill Germanakos and Hollie Self Bring The Biggest Loser Million Pound Tour Presented by MSN to Arizona Mills Mall 10114 1Bill Germanakos and Hollie Self Bring The Biggest Loser Million Pound Tour Presented by MSN to Arizona Mills Mall 10114 2
...ind these data reassuring", PHILADELPHIA, June 05,...id today that findings from an interim analysis,of...mes and,Regulation of glycemia in Diabetes), a pro...etermine cardiovascular outcomes in more,than 4,40...ence to,the overall cardiovascular safety profile ...
...--Jun 5, 2007 - Elixir,Pharmaceuticals, Inc., anno...n antagonism as a potential method for regulating,...ood glucose. The,data were presented in poster ses... Annual Meeting, being held in Toronto,Canada. El...at and,prevent metabolic disease, as well as preve...
Other Medicine Technology:Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4
(Date:5/20/2008)... Survey also reveals less than 5% trust magazines...RK, May 20 /PRNewswire-USNewswire/ -- The Physicia...jectablesafety.org ) and the health and,beauty com...day released,findings of a joint survey reporting ...ties are safe, and only 58% of consumers feel FDA ...
(Date:5/20/2008)... CHELMSFORD, Mass., May 20 /PRNewswire-FirstCall/...), a leading provider of specialized,high-perform..., and signal,processing applications, announced th...any,s business on Thursday, May 29, 2008 at the Co...ference. The Conference will be,held at the New Yo...
(Date:5/20/2008)...To advance underdeveloped approaches to designing ...f Allergy and Infectious Diseases (NIAID), part of... new program to foster the study of B cells, immun...ity to neutralize HIV. The $15.6 million, five-yea...c foundation of HIV vaccine research through a net...
(Date:5/20/2008)... CHAPEL HILL, N.C., May 20 /PRNewswire/ -- New re...isition integration and competitive,intelligence d...able in the,Best Practice Database, an online rese... firm Best Practices, LLC., To review sample key ...,landing page with links to each study at this add...
Breaking Medicine News(10 mins):Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 2Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 3Health News:New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables 4Health News:Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008 2Health News:NIAID to advance B-cell approach to HIV vaccines 2Health News:NIAID to advance B-cell approach to HIV vaccines 3Health News:Best Practice Database Adds Research on Merger Integration and Competitive Intelligence 2
... a patient’s specific culture into consideration c...e incidence of diabetes-related complications over...er management results in reduced long-term complic...utation and nerve damage,” said lead researcher To...
...an, who was rushed to a city hospital here Sunday ...er and recovering from severe exertion, hospital s...but will be kept under observation for the next tw...ital dean N. Trivedi. Saif, 36, was rushed to Li...
...ng Victorian hospital staff could be putting the h...n and control experts. A study published in the ...n half of Victorian health workers in public hospi...ugh the vaccine is provided free through the natio...
...ins is under pressure- he is asked to respond to a... Muckamore Abbey Hospital, which ‘cares’ for peopl...ckamore Abbey Hospital, which houses around 100 ad...der police investigation. The issue came about wh...
Other Medicine News:Health News:Culturally Specific Diabetes Management Helps Low-Income Patients 2
...ast VenaFlow System (a prophylaxis for DVT), VenaF...calf, foot, and thigh, to suit individual physicia... comfortable material to promote increased patient...d directly against the skin. With a slight adjustm...
A new cast boot specially lasted for fiberglass casts... and built on a double rocker sole for easy ambulation! ,The SlimLine boot is built around a narrow last so it fits better than the old plaste
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption.
...real-time polymerase chain reaction (PCR) to ampli...to fully automate and integrate all the steps requ..., DNA amplification and detection. Designed to sim...R test results from a raw sample in 30 minutes or ...
Medicine Products: